申请人:Sumitomo Pharmaceuticals Company, Limited
公开号:EP1184367A1
公开(公告)日:2002-03-06
A prodrug of the compound given by formula:
wherein Ar is an optionally substituted phenyl group or optionally substituted aromatic heterocyclic group; n is an integer of 0, 1 or 2;
R1 is a hydogen atom or an optionally substituted alkyl group; R2 and R3 are independently an optionally substituted alkyl group, or R2 may be bonded with R1 or R3 and taken together with the carbon atom adjacent thereto to form an optionally substituted cycloalkane ring;
R4 and R5 are independently hydrogen atom or an optionally substituted alkyl group;
R6 is a hydrogen atom, hydroxy group or alkyl group;
which is useful as a medicament for treating neurodegenerative disorders such as retinal neurodegenerative disorders and the like.
式所给化合物的原药:
其中 Ar 是任选取代的苯基或任选取代的芳香杂环基团;n 是 0、1 或 2 的整数;
R1 是一个氢原子或一个任选取代的烷基;R2 和 R3 独立地是一个任选取代的烷基,或者 R2 可以与 R1 或 R3 键合,并与相邻的碳原子一起形成一个任选取代的环烷环;
R4 和 R5 独立地为氢原子或任选取代的烷基;
R6 是氢原子、羟基或烷基;
可用作治疗神经退行性疾病(如视网膜神经退行性疾病等)的药物。